These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 3472139)

  • 1. Oral scopolamine hydrobromide solution as an antisialagogic agent in dentistry.
    Markkanen YJ; Pihlajamäki K
    Oral Surg Oral Med Oral Pathol; 1987 Apr; 63(4):417-20. PubMed ID: 3472139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum antimuscarinic activity after a single dose of oral scopolamine hydrobromide solution measured by radioreceptor assay.
    Markkanen YJ; Laurén L; Peltomäki T
    Oral Surg Oral Med Oral Pathol; 1987 May; 63(5):534-8. PubMed ID: 3295650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of transdermal scopolamine on salivation.
    Gordon C; Ben-Aryeh H; Attias J; Szargel R; Gutman D
    J Clin Pharmacol; 1985 Sep; 25(6):407-12. PubMed ID: 4056076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic absorption of ocular scopolamine in patients.
    Lahdes K; Huupponen R; Kaila T; Salminen L; Iisalo E
    J Ocul Pharmacol; 1990; 6(1):61-6. PubMed ID: 2193993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nebulized scopolamine in the management of oral dribbling: three case reports.
    Zeppetella G
    J Pain Symptom Manage; 1999 Apr; 17(4):293-5. PubMed ID: 10203882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study of the effects of oral and i.m. atropine and hyoscine in volunteers.
    Mirakhur RK
    Br J Anaesth; 1978 Jun; 50(6):591-8. PubMed ID: 666935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the cholinomimetic SDZ ENS-163 on scopolamine-induced cognitive impairment in humans.
    Brass EP; Polinsky R; Sramek JJ; Moore M; Jones D; Veroff AE; Wardle TS; Cutler NR
    J Clin Psychopharmacol; 1995 Feb; 15(1):58-62. PubMed ID: 7714229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scopolamine alone or combined with ephedrine in seasickness: a double-blind, placebo-controlled study.
    Laitinen LA; Tokola O; Gothoni G; Vapaatalo H
    Aviat Space Environ Med; 1981 Jan; 52(1):6-10. PubMed ID: 7011299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transdermal scopolamine in drooling.
    Brodtkorb E; Wyzocka-Bakowska MM; Lillevold PE; Sandvik L; Saunte C; Hestnes A
    J Ment Defic Res; 1988 Jun; 32 ( Pt 3)():233-7. PubMed ID: 3047394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies of drugs given before anaesthesia. XVII: anticholinergic premedicants.
    Mirakhur RK; Dundee JW; Connolly JD
    Br J Anaesth; 1979 Apr; 51(4):339-45. PubMed ID: 380608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Volume and pH of gastric contents following anticholinergic premedication.
    Mirakhur RK; Reid J; Elliott J
    Anaesthesia; 1979 May; 34(5):453-7. PubMed ID: 38680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Supersensitivity of salivation in response to pilocarpine after withdrawal of chronically administered hyoscine in the mouse.
    Parkes MW; Parks JC
    Br J Pharmacol; 1972 Oct; 46(2):315-23. PubMed ID: 4675649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NTP Toxicology and Carcinogenesis Studies of Scopolamine Hydrobromide Trihydrate (CAS No. 6533-68-2) in F344 Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1997 Mar; 445():1-277. PubMed ID: 12594530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal scopolamine: human performance and side effects.
    Gordon C; Binah O; Attias J; Rolnick A
    Aviat Space Environ Med; 1986 Mar; 57(3):236-40. PubMed ID: 3964152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dose-dependent telenzepine inhibition of the secretion of human gastric acid stimulated by sham feeding and saliva].
    Müller P; Dammann HG; Simon B
    Z Gastroenterol; 1986 Mar; 24(3):152-6. PubMed ID: 3705659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological effects and pharmacokinetics of atipamezole, a novel alpha 2-adrenoceptor antagonist--a randomized, double-blind cross-over study in healthy male volunteers.
    Karhuvaara S; Kallio A; Scheinin M; Anttila M; Salonen JS; Scheinin H
    Br J Clin Pharmacol; 1990 Jul; 30(1):97-106. PubMed ID: 1975199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of swallowing frequency and transdermal scopolamine on esophageal acid clearance.
    Allen ML; Orr WC; Woodruff DM; Duke JC; Robinson MG
    Am J Gastroenterol; 1985 Sep; 80(9):669-72. PubMed ID: 4036944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study.
    Khajavi D; Farokhnia M; Modabbernia A; Ashrafi M; Abbasi SH; Tabrizi M; Akhondzadeh S
    J Clin Psychiatry; 2012 Nov; 73(11):1428-33. PubMed ID: 23146150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of central and peripheral pharmacologic effects of biperiden and trihexyphenidyl in human volunteers.
    Guthrie SK; Manzey L; Scott D; Giordani B; Tandon R
    J Clin Psychopharmacol; 2000 Feb; 20(1):77-83. PubMed ID: 10653212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of alcohol and transdermally administered scopolamine.
    Gleiter CH; Antonin KH; Schoenleber W; Bieck PR
    J Clin Pharmacol; 1988 Dec; 28(12):1123-7. PubMed ID: 3243930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.